Atopic dermatitis (eczema) trials in Czechia

In Czechia 17 Also abroad 251

17 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
Where
Hlouska, Nový Jičín
Age
6 months to 11 years
People
195 worldwide
Run by
LEO Pharma
See details and how to joinNCT06311682 · EU 2023-503630-44-00
Phase 3Not yet taking people in Czechia
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis
Where
Nový Jičín, Olomouc, Povel, Prague, Prague 10
People
150 worldwide
Run by
Hunan Mabgeek Biotech Co. Ltd.
See details and how to join2025-525022-35-00 · EU 2025-525022-35-00
Phase 2Taking people
A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
Where
Moravska Ostrava A Privoz, Náchod, Pardubice I, Prague 3
Age
18 years to 64 years
People
165 worldwide
Run by
Pfizer
See details and how to joinNCT07216027 · EU 2025-522965-31-00
Phase 2Taking people
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
Where
Prague
Age
18 years and over
People
350 worldwide
Run by
Apogee Therapeutics, Inc.
See details and how to joinNCT07003425
Phase 2Taking people
A Phase 2b Study of the Effects of Camoteskimab in Adults with Moderate-to-Severe Atopic Dermatitis
Where
Moravska Ostrava A Privoz, Pardubice I, Prague, Prague 10
Age
18 years and over
People
138 worldwide
Run by
Apollo Therapeutics Limited
See details and how to join2026-525673-39-00 · EU 2026-525673-39-00
Phase 3Enrolling by invitation
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
Where
Brno-Sever, Prague
Age
6 months to 18 years
People
338 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT05735483 · EU 2022-501478-21-00
Phase 2Not yet taking people in Czechia
A study to investigate the efficacy and safety of TRIV-573 compared with placebo in participants with moderate to severe atopic dermatitis
Where
Moravska Ostrava A Privoz, Nový Jičín, Olomouc, Pardubice I, Prague, Prague 10
Age
18 years and over
People
43 worldwide
Run by
Triveni Bio Inc.
See details and how to join2026-526485-25-00 · EU 2026-526485-25-00
Phase 3Taking people
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
Where
Brno-Stred, Moravska Ostrava A Privoz, Pardubice I, Povel, Prague
Age
12 years and over
People
510 worldwide
Run by
Nektar Therapeutics
See details and how to joinNCT07690371 · EU 2025-524925-42-00
Phase 2Not yet taking people in Czechia
A study to Evaluate the Efficacy and Safety of ENV-294 in Adult Participants with Moderate-to-Severe Atopic Dermatitis
Where
Brno-Stred, Pardubice I, Prague, Prague 10, Praha 1
Age
18 years and over
People
96 worldwide
Run by
Enveda Therapeutics Inc.
See details and how to join2026-526184-38-00 · EU 2026-526184-38-00
Phase 2Taking people
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
Where
Plzen 3, Prague, Prague 3
Age
18 years to 100 years
People
224 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06947993 · EU 2024-519081-49-00
Phase 3Taking people
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
Where
Náchod, Olomouc, Prague, Usti Nad Labem
Age
12 years and over
People
510 worldwide
Run by
Nektar Therapeutics
See details and how to joinNCT07711418 · EU 2025-525129-11-00
Phase 1Taking people
A Phase 1 first-in-human study to evaluate SAR447754 in healthy adult participants and in adult participants with moderate-to-severe atopic dermatitis.
Where
Pardubice I, Prague
Age
18 years to 64 years
People
291 worldwide
Run by
Sanofi-Aventis Recherche & Developpement
See details and how to join2025-523826-41-00 · EU 2025-523826-41-00
Phase 2Taking people
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
Where
Ostrava, Pardubice, Prague
Age
18 years to 65 years
People
280 worldwide
Run by
Apollo Therapeutics Ltd
See details and how to joinNCT07599813
Phase 2Taking people
A Study to Evaluate the Long-term Safety and Effectiveness of APG777 in Subjects with Atopic Dermatitis
Where
Prague, Prague 10, Praha 1
Age
18 years and over
People
175 worldwide
Run by
Apogee Therapeutics Inc.
See details and how to join2024-519795-11-00 · EU 2024-519795-11-00
Phase 2Taking people
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
Where
Moravska Ostrava A Privoz, Nový Jičín, Pardubice I, Prague, Prague 10
Age
18 years to 74 years
People
405 worldwide
Run by
Inmagene LLC
See details and how to joinNCT07037901 · EU 2024-520117-50-00
Phase 2Taking people
Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD
Where
Pardubice I, Prague, Prague 10
Age
18 years and over
People
200 worldwide
Run by
Corvus Pharmaceuticals, Inc.
See details and how to joinNCT07441395 · EU 2025-524384-20-00
Phase 3Taking people
Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.
Where
Moravska Ostrava A Privoz, Pardubice I, Prague, Prague 10
Age
18 years and over
People
277 worldwide
Run by
medac GmbH
See details and how to joinNCT06239311 · EU 2023-504443-13-00